Standard BioTools (LAB) expects fourth quarter 2024 revenue of approximately $46.5M and full year 2024 revenue of approximately $174M. “The ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.16% of ...
13d
U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Monday. Shares of Intra-Cellular Therapies, Inc.
Preliminary, unaudited revenue for the full year 2024 of approximately $174 millionPresenting at the 43rd Annual J.P. Morgan Healthcare ...
In recent trading, Standard Biotools Inc (LAB) stock price has shown some volatility, fluctuating 13.19% over the last five trades and 1 ...
OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback